Skip to content
    IMVT
    Earnings call· Jun 2026(Q1 FY27)

    Immunovant Q1 FY27 earnings call IMVT

    Aug 6, 2026 Source

    Executive summary

    Immunovant Q1 FY27 — Busy Pipeline Ahead of Key Readouts and Launch

    Immunovant reported a quiet quarter, but highlighted significant upcoming catalysts, including the imminent potential launch of brexpiprazole in dermatomyositis. The company is preparing for a "jampacked second half" with multiple top-line data readouts and program updates across its pipeline, including NIU, PH-ILD, and DroTRA. Management emphasized a "slow and steady" launch approach for brexpiprazole DM to build a strong foundation for future indications, while also progressing litigation and capital return initiatives.

    Highlights

    4

    • Brexpiprazole Phase III study in cutaneous sarcoidosis initiated ahead of schedule, following positive Phase II data showing a >20-point benefit on the CSAMI scale.

    • Initial $950 million payment from Moderna settlement received, with approximately $770 million allocated to Genevant.

    • Significant share repurchase activity, with about $200 million executed in the quarter at an average price in the high $20s.

    • Brexpiprazole DM launch is on track for imminent potential approval and launch by the end of September.

    Concerns

    3

    • Lack of clear signal on 6-minute walk distance in PH-ILD study

    • Variability in placebo response rates in NIU Phase III study

    • Physician concerns about JAK class safety profile for Brexpiprazole

    Guidance & targets

    7
    CategoryTargetConfidence
    Brexpiprazole launch in dermatomyositis (DM)
    Expected launch
    high materiality
    High
    Brexpiprazole NIU study top-line data
    Top-line data readout
    high materiality
    High
    Mosely (PH-ILD) Phase III study top-line data
    Top-line data readout
    high materiality
    High
    DroTRA program updates (Immunovant)
    Updates including FDA conversation and study results
    medium materiality
    High
    POC study in CLE top-line data
    Top-line data readout
    low materiality
    High
    Brexpiprazole cutaneous sarcoidosis (CS) Phase III top-line data
    Top-line data readout
    medium materiality
    High
    Overall catalyst calendar
    3+ commercial launches, 9 study readouts, 4+ NDA/BLA filings, number of proof-of-concept studies
    high materiality
    High

    Operational metrics

    7
    R&D expense
    $200M
    Q1 FY27

    For the quarter.

    Non-GAAP adjusted G&A expense
    Under $100M
    Q1 FY27

    For the quarter.

    GAAP G&A expense
    $166M
    Q1 FY27

    For the quarter.

    Cash and investments balance
    Under $4B
    Q1 FY27

    Before the receipt of the $772 million from the Moderna settlement.

    Share repurchase amount
    $200Ma bit more than that when you include March
    Q1 FY27

    Accelerated share repurchase program upon announcement of Moderna settlement.

    Moderna settlement payment received
    $950M
    Q1 FY27

    Initial payment from patent infringement settlement.

    Potential Moderna settlement payment (498 part)
    $1.3B
    Future

    Potential amount if favorable outcome in the appellate ruling for the '498 part of the case.

    Industry KPIs

    3
    MetricValueDetails
    Pipeline read out calendar9 study readouts, 4+ NDA/BLA filings, 3+ commercial launches
    Regulatory approvals filingsPDUFA date this quarter
    Clinical trial efficacy safety dataGreater than 20-point benefitpoints

    Deals & partnerships

    2
    ModernaPatent infringement settlement$950 million

    Initial payment received from the settlement.

    Pfizer and BioNTechPatent infringement litigation$1.3 billion

    Filed 3 international lawsuits in July (Canada and UPC).

    Risks & headwinds

    3
    Lack of clear signal on 6-minute walk distance in PH-ILD studyH2 FY27

    not powered for 6-minute walk

    Mitigation: Study designed with emphysema in mind; focus on PVR signal as primary indicator of benefit.

    Variability in placebo response rates in NIU Phase III studyH2 FY27

    we don't know exactly what placebo response rates will be in that study

    Mitigation: Phase II data was compelling, indicating high drug activity; geographic variation is a known feature of immunology studies.

    Physician concerns about JAK class safety profile for BrexpiprazoleNear-term (launch)

    JAK class safety concerns

    Mitigation: DM patients have high unmet need and are often on therapies (e.g., high-dose steroids) with worse safety concerns; physicians are generally comfortable using JAKs in this context.

    What to watch in Q2 FY27

    5

    Brexpiprazole DM launch

    Q3 FY27 (by end of September)
    CurrentPDUFA date this quarter, launch expected by end of September
    TargetApproval and commercial launch

    Why it matters

    First commercial launch for a targeted therapy in dermatomyositis, critical for establishing market presence and future growth.

    brexpiprazole expected to launch by the end of September.

    Q&A highlights

    7

    What metrics will be provided for the DM launch? Are there implications of sotatercept use in PH-ILD for 6-minute walk and PVR?

    The company will not provide extensive early metrics for the DM launch, focusing on internal understanding. For PH-ILD, the study was designed considering emphysema, and vasodilation is expected to drive benefit. A clear PVR signal is anticipated, but the study is not powered for 6-minute walk distance.

    “I don't know that we're going to provide a ton of detail in the early days. I think it's important for us mostly to spend our time focused on understanding those dynamics ourselves, getting out, talking to patients, talking to physicians, doing the work we need to do.”

    asked by Lut Ming Cheng · answered by Matthew Gline

    2 min read5 chapters

    Detailed Narrative

    01

    Brexpiprazole DM Launch Strategy

    Management outlined a "slow and steady" approach for the brexpiprazole launch in dermatomyositis (DM), expected by the end of September. This strategy prioritizes building a strong foundation around patient access, support, and scientific communication over rapid initial uptake. The goal is to maximize the long-term opportunity for brexpiprazole across its multiple potential indications, including non-infectious uveitis (NIU), cutaneous sarcoidosis (CS), and lichen planopilaris (LPP).

    02

    Pipeline Progress and Upcoming Catalysts

    The company anticipates a "jampacked second half" of 2026, with several key data readouts. These include top-line data for brexpiprazole in NIU, Mosely (PH-ILD) Phase III data, and proof-of-concept data for brexpiprazole in cutaneous lupus erythematosus (CLE). Additionally, updates on the DroTRA program, including an FDA conversation and study results, are expected. The Phase III study for brexpiprazole in cutaneous sarcoidosis has already begun enrolling patients, with top-line data anticipated in 2028.

    03

    Moderna Settlement and Litigation Update

    Immunovant has received the initial $950 million payment from the Moderna settlement, with approximately $770 million directed to Genevant. The company is also actively pursuing litigation against Pfizer and BioNTech, having filed three international lawsuits in July, with a potential for an additional $1.3 billion if a favorable outcome is achieved in the '498 part of the case.

    04

    Financial Highlights and Capital Allocation

    For Q1 FY27, the company reported approximately $200 million in R&D expense, under $100 million in non-GAAP adjusted G&A, and $166 million in GAAP G&A. Cash and investments stood at just under $4 billion before the Moderna settlement payment. Following the settlement, the company accelerated its share repurchase program, buying back about $200 million in the quarter at an average price in the high $20s, and plans to continue repurchases under existing authorizations.

    05

    Brexpiprazole in Cutaneous Sarcoidosis (CS)

    The Phase III study for brexpiprazole in cutaneous sarcoidosis has commenced enrollment ahead of schedule. The study is designed for 140 patients, randomized 3:2 to 45mg brexpiprazole or placebo over 16 weeks, with a mandatory steroid taper. The primary endpoint is a ≥50% response rate on the CSAMI scale, building on Phase II data that showed a >20-point benefit compared to placebo, exceeding the clinical meaningfulness goal of a 5-point benefit.

    AI-generated summary of the company’s earnings call. Not investment advice.